



15.05.2024

11:30 - 12:30 **Type: Industry Satellite Symposium** **Hamburg Hall**
Title: Daiichi Sankyo | AstraZeneca - Many patients, many needs: Challenging HER2-expressing metastatic breast cancer cases
Chair(s): Marc Thill, Germany

11:30 - 11:35 **Welcome and introduction**
Marc Thill, Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, Germany

11:35 - 11:50 **From the pathology lab: The importance of accurate HER2 testing to optimise the identification of patients eligible for HER2-targeted therapies**
Caterina Marchiò, IRCCS - Istituto di Candiolo - FPO, Candiolo, Italy

11:50 - 12:05 **An oncologist's perspective: My approach to treating challenging HER2-expressing metastatic breast cancer cases**
François Clément Bidard, Institut Curie, Paris, France

12:05 - 12:20 **Safety in focus: Management of patients with HER2-expressing metastatic breast cancer**
Marc Thill, Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, Germany

12:20 - 12:30 **Panel discussion and Q&A**



11:30 - 12:30	Type: Industry Satellite Symposium Title: Pfizer - The path to strategic sequencing in 3L HER2+ metastatic breast cancer Chair(s): Sara Tolaney, United States of America	Munich Hall
11:30 - 11:35	Welcome <u>Sara Tolaney</u> , Dana Farber Cancer Institute, Boston, United States of America	
11:35 - 11:45	Reading the chessboard: Transformation and opportunities in the treatment landscape of HER2+ MBC <u>Sara Tolaney</u> , Dana Farber Cancer Institute, Boston, United States of America	
11:45 - 12:00	CNS defence: A case-based conversation about the threat of CNS involvement and clinical decision-making in HER2+ MBC <u>Rupert Bartsch</u> , Medizinische Universitaet Wien, Vienna, Austria	
12:00 - 12:15	Moving forward: A case-based conversation on clinical decision-making in 3L post T-DXd progression and future directions in HER2+ MBC <u>Carmen Criscitiello</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy	
12:15 - 12:25	Panel discussion and audience Q&A	
12:25 - 12:30	Closing remarks <u>Sara Tolaney</u> , Dana Farber Cancer Institute, Boston, United States of America	



11:30 - 12:30	Type: Industry Satellite Symposium Title: Medscape Oncology Global - Real-world HER2-positive early breast cancer: Optimising curative intent therapy Chair(s): Volkmar Mueller, Germany	Frankfurt Hall
11:30 - 11:35	Welcome and introduction <u>Volkmar Mueller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany	
11:35 - 11:50	Optimizing HER2+ early breast cancer management: Where are we today? <u>Volkmar Mueller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany	
11:50 - 12:00	Living with HER2: Understanding the road to survivorship <u>Lesley Fallowfield</u> , Brighton and Sussex Medical School - University of Sussex, Brighton, United Kingdom	
12:00 - 12:10	Addressing disparities between clinical trials and clinical practice: From phase III to real-world setting <u>Qiang Liu</u> , Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China	
12:10 - 12:25	Navigating critical decision points in care pathways: Exploring best practices across borders <u>Volkmar Mueller</u> ¹ , <u>Lesley Fallowfield</u> ² , <u>Qiang Liu</u> ³ , ¹ UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany, ² Brighton and Sussex Medical School - University of Sussex, Brighton, United Kingdom, ³ Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China	
12:25 - 12:30	Q&A session and concluding remarks <u>Volkmar Mueller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany	
12:30 - 13:00	Type: Lunch break Title: Welcome Reception	Exhibition area



13:00 - 13:40	Type: Opening and Keynote lecture Title: Welcome to the ESMO Breast Cancer 2024 and Keynote lecture 1	Berlin Hall
13:00 - 13:10	Opening session	
13:10 - 13:15	Introduction to Keynote lecture 1	
13:15 - 13:40	Making personalized precision medicine a reality for breast cancer in 2024 <u>Nadia Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, Germany	
14:00 - 15:30	Type: Educational session Title: Post neoadjuvant systemic treatment decisions Chair(s): Carmen Criscitiello, Italy; Erika Hamilton, United States of America	Berlin Hall
14:00 - 14:20	Decision making in post-neoadjuvant setting: The role of pCR, RCB, ctDNA, TILs and molecular features <u>Carsten Denkert</u> , UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, Germany	
14:20 - 14:40	Triple negative breast cancer (TNBC): Is there a standard treatment and does one size fit all? <u>Helena Earl</u> , Addenbrooke's Hospital, Cambridge, United Kingdom	
14:40 - 15:00	HER2-positive: De-escalation and escalation strategies <u>Evandro De Azambuja</u> , Institute Jules Bordet, Brussels, Belgium	
15:00 - 15:20	HR-positive/HER2-negative: When to use CDK4/6 inhibitors, including gBRCA1/2mut patients? <u>Carmen Criscitiello</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy	
15:20 - 15:30	Q&A and discussion	



14:00 - 15:30 **Type: Educational session** **Hamburg Hall**
Title: Clinical trials design: Novel designs
Chair(s): Sara Tolaney, United States of America; Stefan Michiels, France

14:00 - 14:20 **Designing neoadjuvant clinical trials: What is the right endpoint?**

14:20 - 14:40 **Novel clinical trial strategies for de-escalation of therapy**
Sara Tolaney, Dana Farber Cancer Institute, Boston, United States of America

14:40 - 15:00 **Unlocking the potential of biomarker-based trial designs in advancing new therapeutics**
Tomás Pascual, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

15:00 - 15:20 **Statistical considerations in new clinical trials design**
Stefan Michiels, Institut Gustave Roussy, Villejuif, Cedex, France

15:20 - 15:30 **Q&A and discussion**

14:00 - 15:30 **Type: Educational session** **Munich Hall**
Title: Practice changes based on real-world data
Chair(s): Suzette Delaloge, France; Peter A. Fasching, Germany

14:00 - 14:20 **Secondary use of existing health data for real-world analyses**
Antonis Valachis, Cancercentrum, Eskilstuna, Sweden

14:20 - 14:40 **Utilisation of real-world data for the pre marketing evaluations in oncology**
Diogo Martins Branco, ESMO - European Society for Medical Oncology, Lugano, Switzerland

14:40 - 15:00 **Machine learning/artificial intelligence (AI) in real-world analyses**
Suzette Delaloge, Institut Gustave Roussy, Villejuif, Cedex, France

15:00 - 15:20 **Biomarker discovery and validation in the real-world setting**
Hanna Huebner, Universitätsklinik Erlangen, Erlangen, Germany

15:20 - 15:30 **Q&A and discussion**



15:45 - 16:15	Type: Keynote lecture Title: Keynote lecture 2	Berlin Hall
15:45 - 15:50	Introduction by the Chair	
15:50 - 16:15	Evolutionary histories of breast cancer and related clones <u>Tomomi Nishimura</u> , Graduate School of Medicine and Faculty of Medicine Kyoto University, Kyoto, Japan	
16:15 - 16:45	Type: Coffee break Title: Coffee Break	Exhibition area
16:45 - 17:55	Type: Proffered Paper session Title: Proffered Paper session 1 Chair(s): Erika Hamilton, United States of America; Masakazu Toi, Japan	Berlin Hall
16:45 - 16:57	1790 - Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): results of the international phase II DOLAF trial. <u>S��verine Guiu</u> , ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, France	
16:57 - 17:09	1800 - IMpassion132 double-blind randomised phase 3 trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC) <u>Rebecca Dent</u> , National Cancer Centre Singapore, Singapore, Singapore	
17:09 - 17:21	1810 - Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC) <u>Peter Schmid</u> , Barts Cancer Institute, Queen Mary University of London, BQ, United Kingdom	
17:21 - 17:36	Invited Discussant 1790, 1800 and 1810 <u>Sara Tolaney</u> , Dana Farber Cancer Institute, Boston, United States of America	
17:36 - 17:51	Q&A and discussion	



16:45 - 18:15 **Type: Educational session** **Hamburg Hall**
Title: Dynamics response and biomarkers-based treatment decisions for early breast cancer
Chair(s): Christine Desmedt, Belgium; Marleen Kok, Netherlands

16:45 - 17:05 **Challenges and opportunities for biomarker research in the pre-operative setting**
Laura Van'T Veer, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, United States of America

17:05 - 17:25 **Tissue and blood-based biomarkers of response to immunotherapy**
Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands

17:25 - 17:45 **Heterogeneity of treatment targets and markers of treatment resistance in metastatic breast cancer: Lessons learned from research autopsies**
Christine Desmedt, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium

17:45 - 18:05 **Liquid biopsies: Current use, opportunities and challenges in metastatic breast cancer**
Nicholas Turner, The Royal Marsden Hospital - Chelsea, London, United Kingdom

18:05 - 18:15 **Q&A and discussion**

16:45 - 18:15 **Type: Educational session** **Munich Hall**
Title: Actionability of germline variants beyond BRCA 1 and 2
Chair(s): Shani Paluch-Shimon, Israel; Kelly-Anne Phillips, Australia

16:45 - 17:05 **Individual tailoring of risk assessment for germline variants beyond BRCA**
Kelly-Anne Phillips, Peter MacCallum Cancer Center, Melbourne, Australia

17:05 - 17:25 **BRCA1/2 and beyond: The surgeons perspective**
Peter Dubsy, Hirslanden Klinik St. Anna, Lucerne, Switzerland

17:25 - 17:45 **Clinical phenotypes of hereditary breast cancer beyond BRCA**
Shani Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, Israel

17:45 - 18:05 **Systemic therapy horizons for hereditary breast cancer beyond BRCA**
Judith Balmaña, Vall d'Hebron University Hospital, Barcelona, Spain

18:05 - 18:15 **Q&A and discussion**



18:30 - 19:30	Type: Industry Satellite Symposium Title: Pfizer - Tailoring journeys: Customised care with CDK4/6 inhibitors in HER2- metastatic breast cancer Chair(s): Richard Finn, United States of America	Hamburg Hall
18:30 - 18:35	Welcome and introduction <u>Richard Finn</u> , UCLA - David Geffen School of Medicine, Los Angeles, United States of America	
18:35 - 18:45	The current and future treatment landscape for ER+/HER2- metastatic breast cancer setting <u>Renate Haidinger</u> , Brustkrebs Deutschland e.V., Hohenbrunn, Germany	
18:45 - 19:00	An encompassing journey: Shaping clinical decisions <u>Richard Finn</u> , UCLA - David Geffen School of Medicine, Los Angeles, United States of America	
19:00 - 19:15	A unique journey: Personalising approaches <u>Antonio Llombart Cussac</u> , Hospital Arnau de Vilanova, Valencia, Spain	
19:15 - 19:25	Panel discussion and audience Q&A	
19:25 - 19:30	Closing remarks <u>Richard Finn</u> , UCLA - David Geffen School of Medicine, Los Angeles, United States of America	



18:30 - 19:30 **Type: Industry Satellite Symposium** **Munich Hall**
Title: Menarini Stemline - Current and upcoming treatment strategies after CDK4/6 inhibitors for patients with ER+/HER2- advanced breast cancer

18:30 - 18:35 **Overview of the ESMO BC living guidelines in ER+/HER2- metastatic breast cancer setting**

18:35 - 18:55 **The current and future treatment landscape for ER+/HER2- metastatic breast cancer setting**

18:55 - 19:10 **Emerging biomarkers in breast cancer: Implementing liquid biopsy ESR1 mutation testing**

19:10 - 19:30 **Clinical experience and takeaways**

18:30 - 19:30 **Type: Industry Satellite Symposium** **Frankfurt Hall**
Title: AstraZeneca - Advances in a dynamic disease: A patient-first approach to HR-positive mBC
Chair(s): Sibylle Loibl, Germany

18:30 - 18:35 **The evolving treatment paradigm in HR-positive, HER2-negative/low mBC**
Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany

18:35 - 18:45 **Targeted strategies: ET-based combinations in 2L HR-positive disease**
Mafalda Oliveira, Vall d'Hebron University Hospital, Barcelona, Spain

18:45 - 18:55 **New frontiers: Exploring options post-ET with ADCs**
Aditya Bardia, UCLA - David Geffen School of Medicine, Los Angeles, United States of America

18:55 - 19:25 **Putting patients first: An interactive case discussion**

19:25 - 19:30 **Summary and close**
Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany



16.05.2024

08:30 - 10:00 **Type: Educational session** **Berlin Hall**
Title: New ADCs joining the field
Chair(s): Matteo Lambertini, Italy; Rebecca Dent, Singapore

08:30 - 08:50 **Shedding lights on the evolving landscape of ADC development**
Matthias Peipp, Christian-Albrechts-University Kiel, Kiel, Germany

08:50 - 09:10 **New promising targets beyond HER2 and TROP2**
Erika Hamilton, Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America

09:10 - 09:30 **Combination strategies: Focus on ADCs and IO-based strategies**
Rebecca Dent, NCCS - National Cancer Centre Singapore, Singapore, Singapore

09:30 - 09:50 **Next steps for ADCs in managing brain metastases**
Rupert Bartsch, Medizinische Universitaet Wien, Vienna, Austria

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:00 **Type: Mini Oral session** **Munich Hall**
Title: Mini Oral session 1
Chair(s): Peter A. Fasching, Germany; Thomas Bachelot, France; Cristina Saura Manich, Spain

08:30 - 08:35 **182MO - Trastuzumab deruxtecan (T-DXd) vs Treatment of Physician's Choice (TPC) in Patients (pts) With HER2+ Metastatic Breast Cancer (mBC) Previously Treated With Trastuzumab Emtansine (T-DM1): Updated Overall Survival (OS) Results of the Randomized, Phase 3 DESTINY-Breast (DB-)02 Study**
Sung-Bae Kim, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

08:35 - 08:40 **267MO - Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) Retreatment (RTx) After Recovery From Grade (Gr) 1 Interstitial Lung Disease/Pneumonitis (ILD)**
Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America

08:40 - 08:45 **One LBA TBC**

08:45 - 09:03 **Invited Discussant 182MO, 267MO and one LBA TBC**
Peter A. Fasching, University Hospital Erlangen, Erlangen, Germany

09:03 - 09:08 **183MO - Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): second**



progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPitello-291 trial

Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America

09:08 - 09:13 **1MO - HER2DX assay and survival outcomes: an individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer**

Guillermo Villacampa Javierre, VHIO Vall d'Hebron Institute of Oncology, Barcelona, Spain

09:13 - 09:18 **2MO - Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2- metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial**

Mafalda Oliveira, Vall d'Hebron University Hospital and Breast Cancer Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain

09:18 - 09:36 **Invited Discussant 183MO, 1MO and 2MO**

Thomas Bachelot, Centre Léon Bérard, Lyon, France

09:36 - 09:41 **3MO - Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE**

Christine Desmedt, KU Leuven, Leuven, Belgium

09:41 - 09:46 **4MO - Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: a translational analysis**

Paul Cottu, Institut Curie, Paris, France

09:46 - 09:59 **Invited Discussant 3MO and 4MO**

Cristina Saura Manich, Vall d'Hebron University Hospital, Barcelona, Spain



08:45 - 09:45	Type: Controversy session Title: Is low dose endocrine therapy the new standard for breast cancer chemo prevention? Chair(s): Javier Cortés, Spain	Hamburg Hall
08:45 - 08:55	Introduction and first vote <u>Javier Cortés</u> , INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, Spain	
08:55 - 09:15	Yes <u>Andrea De Censi</u> , Ente Ospedaliero Ospedali Galliera, Genova, Italy	
09:15 - 09:35	No <u>Gareth Evans</u> , The University of Manchester, Manchester, United Kingdom	
09:35 - 09:45	Second vote and conclusions/discussion <u>Javier Cortés</u> , INTERNATIONAL BREAST CANCER CENTER, IBCC, Barcelona, Spain	
10:00 - 10:30	Type: Coffee break Title: Coffee Break	Exhibition area
10:30 - 12:00	Type: Educational session Title: Management of toxicities of the most recent drugs in the breast cancer field Chair(s): Etienne Brain, France; Janice Wing-Hang Tsang, Hong Kong PRC	Berlin Hall
10:30 - 10:45	Managing short and long term toxicities of immuotherapy <u>Mafalda Oliveira</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
10:45 - 11:00	Insights into management of toxicities of ADCs including rechallenge <u>Peter Schmid</u> , Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom	
11:00 - 11:15	Managing the toxicities of various small molecule inhibitors: Are we comfortable? <u>Yen-Shen Lu</u> , NTUH - National Taiwan University Hospital, Taipei City, Taiwan	
11:15 - 11:30	Managing toxicities of the most recent drugs in senior citizens <u>Etienne Brain</u> , Hopital René Huguenin - Institut Curie, Saint-Cloud, France	
11:30 - 11:45	How to partner with patients: Education tools and strategies <u>Eva Schumacher-Wulf</u> , Mamma MIA - The Breast Cancer Magazine, Köln, Germany	
11:45 - 12:00	Q&A and discussion	



10:30 - 12:00	Type: Special Symposium Title: ctDNA for clinical decision making Chair(s): Fabrice André, France; Masakazu Toi, Japan	Hamburg Hall
10:30 - 10:50	Methylome platform for multi-cancer early detection <u>Heather Parsons</u> , Dana-Farber Cancer Institute, Boston, United States of America	
10:50 - 11:10	Liquid biopsy and minimal residual disease <u>Klaus Pantel</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, Germany	
11:10 - 11:30	Predict the future: Early switch strategies and beyond <u>Fabrice André</u> , Gustave Roussy - Cancer Campus, Villejuif, France	
11:30 - 11:50	Liquid biopsy: Monitoring and targeting in the advanced breast cancer setting <u>R. Charles Coombes</u> , Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, United Kingdom	
11:50 - 12:00	Conclusions and clinical perspectives <u>Masakazu Toi</u> , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan	



10:30 - 12:00 **Type: Young Oncologists session** **Frankfurt Hall**
Title: YO Clinical case discussion
Chair(s): Rodrigo Sanchez Bayona, Spain; Pablo Mando, Argentina

10:30 - 10:40 **Clinical case 1: Optimal management of high - risk HR+/HER2- early breast cancer**

10:40 - 10:55 **Mentor guided discussion**
Eva Ciruelos, Hospital Universitario 12 de Octubre, Madrid, Spain

10:55 - 11:05 **Clinical case 2: Caring for exceptional responders with HER2+ metastatic breast cancer**

11:05 - 11:20 **Mentor guided discussion**
Evandro De Azambuja, Institute Jules Bordet, Brussels, Belgium

11:20 - 11:30 **Clinical case 3: Metastatic TNBC with early relapse after completion of neo/adjuvant treatment**

11:30 - 11:45 **Mentor guided discussion**
Sara Tolaney, Dana Farber Cancer Institute, Boston, United States of America

11:45 - 12:00 **Q&A and general discussion**

12:00 - 13:00 **Type: Poster Display session** **Exhibition area**
Title: Lunch and Poster Display session

12:00 - 12:00 **6P - HbA1c as a prognostic biomarker in early breast cancer among patients without diabetes**
Jonas Holm, Aarhus University Hospital, Aarhus N, Denmark

12:00 - 12:00 **7P - Trastuzumab deruxtecan (T-DXd) for Advanced Breast Cancer (ABC) patients (pts), regardless of HER2 status: a phase II study with Biomarkers Analysis (DAISY). Update analysis with longer follow-up.**
Veronique Dieras, Centre Eugène Marquis, Rennes, France

12:00 - 12:00 **8P - Evaluating HER2DX pCR-Score and MRI response in predicting pathologic complete response (pCR) to anti-HER2 neoadjuvant chemotherapy (CT) in early-stage HER2-positive (HER2+) breast cancer (BC)**
Tomás Pascual, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain

12:00 - 12:00 **9P - Plasticity marker FOXC1 expression is a superior predictor of Adjuvant**



Tamoxifen + Chemotherapy efficacy in reducing disease recurrence and all-cause mortality in ER+LN- Breast Cancer: Validation in the SCAN-B Prospective Study (NCT02306096)

Partha Ray, Onsite Healthcare, Lincolnwood, United States of America

- 12:00 - 12:00 **10P - PIK3CA mutation and response to neoadjuvant taselisib and endocrine therapy - a biomarker study of the LORELEI trial**
Danai Fimereli, Institute Jules Bordet, Brussels, Belgium
- 12:00 - 12:00 **11P - Influence of ctDNA Variant Allele Frequency (VAF) on Survival Outcomes in Metastatic Breast Cancer (MBC)**
Isabel Garcia Fructuoso, IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
- 12:00 - 12:00 **12P - Updated findings from the first prospective HER2DX clinical decision impact study on early-stage HER2-positive (HER2+) breast cancer (BC)**
Olga Martínez-Sáez, Hospital Clinic of Barcelona, Barcelona, Spain
- 12:00 - 12:00 **13P - HER2DX ERBB2 mRNA Score in First-Line Metastatic HER2-Positive (HER2+) Breast Cancer (BC): Implications for Treatment Stratification**
Rodrigo Sanchez Bayona, Hospital Universitario 12 de Octubre, Madrid, Spain
- 12:00 - 12:00 **14P - Assessing the Predictive Value of HER2DX pCR-Score for Pathologic Complete Response (pCR) in Early-Stage HER2-Positive (HER2+) Breast Cancer (BC) Under Real-World Conditions**
Olga Martínez-Sáez, Hospital Clinic of Barcelona, Barcelona, Spain
- 12:00 - 12:00 **16P - Determinants of response to short preoperative endocrine therapy (pET) in hormone receptor-positive and HER2-negative (HR+/HER2-) early breast cancer (EBC)**
Raquel Gómez Bravo, Hospital Clinic of Barcelona, Barcelona, Spain
- 12:00 - 12:00 **17P - Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy**
Brendah Masisi, University of Botswana, Gaborone, Botswana
- 12:00 - 12:00 **18P - Prognostic significance of complete cell cycle arrest in patients with HR+HER2- breast cancer receiving neoadjuvant chemotherapy**
Sung Gwe Ahn, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
- 12:00 - 12:00 **19P - HER2-Low prognosis in early breast cancer a canto based study (LILAC)**
Lauriane Durand, Centre Francois Baclesse, Caen, Cedex, France
- 12:00 - 12:00 **20P - Prognostic implications of IGF-1R expression in breast cancer overall and across body mass index groups**
Jonas Holm, Aarhus University Hospital, Aarhus N, Denmark



- 12:00 - 12:00 **21P - Tumor cell expressed SDC1 in breast cancer and breast cancer patient survival.**
Song Yao, Shanghai Tenth People's Hospital, Shanghai, China
- 12:00 - 12:00 **22P - Unveiling biological and prognostic differences among premenopausal patients with hormone receptor-positive HER2-negative (HR+/HER2-) breast cancer**
Benjamin Walbaum, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
- 12:00 - 12:00 **23P - Longitudinal Evaluation of PAM50 Molecular Subtypes in Patients Receiving Neoadjuvant HER2-targeted Therapy in the PREDIX HER2 Trial**
Emmanouil Sifakis, Karolinska Institute, Stockholm, Sweden
- 12:00 - 12:00 **24P - Letrozole and exemestane as serum estrogen suppressors during neoadjuvant therapy in breast cancer patients: a head-to-head comparison**
Jürgen Geisler, Akershus University Hospital HF, Lorenskog, Norway
- 12:00 - 12:00 **25P - Immune Checkpoint gene expression in Breast Carcinoma: Correlation with Clinicopathological features and prognostic value**
Yoel Genaro Montoyo-Pujol, Dr. Balmis General University Hospital - Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain
- 12:00 - 12:00 **26P - Lipidic and T-cell characterization as prognostic biomarkers for patients with ER+ HER2- metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK4/6i)**
Letizia Negrini, University of Eastern Piedmont, Novara, Italy
- 12:00 - 12:00 **27P - Impact of chemotherapy (CT) use and stromal Tumor-Infiltrating Lymphocytes (sTILs) in Stage I Triple Negative Breast Cancer (TNBC)**
Vittoria Barberi, La Sapienza University of Rome | Vall d'Hebron University Hospital | Vall d'Hebron Institute of Oncology, Rome, Italy
- 12:00 - 12:00 **28P - The Ki67 proliferation index in subtypes of human DCIS grade 3 - a biomarker with potential impact on clinical decision making?**
Hossein Schandiz, University of Oslo, Lørenskog, Norway
- 12:00 - 12:00 **29P - Long-term performance of Residual Cancer Burden (RCB), Clinical Pathological Stage (CPS) and CPS+ER+Grade (CPS-EG) models in ER+HER2-breast cancer (BC) patients (pts) after neoadjuvant chemotherapy (NAC): Role of Ki67 drop and extended endocrine therapy (EET)**
Lucia Sanz Gomez, VHIO - Vall d'Hebron Institute of Oncology, Barcelona, Spain
- 12:00 - 12:00 **30P - E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular carcinoma**
Lounes Djerroudi, Institut Curie, Paris, France



- 12:00 - 12:00 **31P - Crown-like structures are associated with changes in immune cell infiltrates and gene signatures in patients with primary invasive breast cancer**
Constantinos Savva, University of Southampton, Southampton, United Kingdom
- 12:00 - 12:00 **32P - Genomic risk classification and whole transcriptome analysis of HR+/HER2- Post-partum breast cancers - A FLEX sub study**
Virginia Borges, University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, United States of America
- 12:00 - 12:00 **33P - Breast cancer brain metastases present a suppressed immune microenvironment enriched in macrophagic components as compared to paired primary tumors**
Gaia Griguolo, University of Padova, Padova, Italy
- 12:00 - 12:00 **34P - Premenopausal Breast Cancer and CYP27A1 expression - a Cholesterol-associated Biomarker**
Jeppe Skovbjerg, Aarhus University and Aarhus University Hospital, Aarhus Universitetshospital, Denmark
- 12:00 - 12:00 **35P - Genomic and Clinical Landscape of Metastatic Hormone Receptors-positive Breast Cancers carrying ESR1 Alterations**
Luca Boscolo Bielo, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy
- 12:00 - 12:00 **36P - Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping and Prognostic Classification**
Evan Paul, MultiplexDX, Bratislava, Slovak Republic
- 12:00 - 12:00 **37P - Employing semi-quantitative methods to classify breast cancer markers (ER, PR, HER2, Ki67) expression, using the RT-qPCR based APIS Breast Cancer Subtyping Kit**
Joanna Gorniak, Apis Assay Technologies Ltd, Manchester, United Kingdom
- 12:00 - 12:00 **38P - Spatial analysis of the tumor microenvironment in hormone receptor-positive (HR+) young women breast cancer (YWBC) from a parity and lactation perspective.**
Miriam Sanso, Institute of Health Research Balearic Islands, Palma, Spain
- 12:00 - 12:00 **39P - Genomic landscape of metaplastic breast cancer from the AACR GENIE database**
Parth Sharma, UMKC (University of Missouri Kansas City), Kansas City, United States of America
- 12:00 - 12:00 **40P - A peculiar chromosome 17 copy number profile stratifies HER2-low breast carcinomas**
Sara Bellomo, Candiolo Cancer Institute - FPO IRCCS, cANDIOLO, Italy
- 12:00 - 12:00 **42P - DPD testing from tumor RNAseq in breast cancer: a proof of concept**



analysis

Kristín Sigurjónsdóttir, Lund University, Lund, Sweden

- 12:00 - 12:00 **43P - Deciphering Spatial Expression of Trop-2, HER2, and AR: Towards Customized Treatments in Triple-Negative Breast Cancer**
Marcela Carausu, Institute Jules Bordet, Brussels, Belgium
- 12:00 - 12:00 **44P - Metaplastic Breast Cancer: Decoding the Molecular Puzzle and Immune Interplay - A Single-Center Experience**
Anna Lea Amylidi, University Hospital of Ioannina, Ioannina, Greece
- 12:00 - 12:00 **45P - Integrated multi-omic analysis of HR+/HER2- breast cancer cell lines resistant to CDK4/6 Inhibitors.**
Cristina Guarducci, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy
- 12:00 - 12:00 **46P - Radiogenomic analysis of breast cancer according to the adjacent parenchymal tissue by using RNA sequencing: Association with background parenchymal enhancement and peritumoral edema on breast MRI.**
Tae Hee Kim, Ajou University School of Medicine, Suwon, Korea, Republic of
- 12:00 - 12:00 **47P - Digital Spatial Profiling Reveals Age-Related Disparities in Immune Microenvironment and Aggressive Phenotypes in Triple-Negative Breast Cancer**
Snijesh V P, SJRI - St. John's Research Institute, Bangalore, India
- 12:00 - 12:00 **48P - Large-scale DNA organization of nuclei in DCIS ducts with adjacent invasive cancer**
Martial Guillaud, BC Cancer Research Center, Vancouver, Canada
- 12:00 - 12:00 **49P - A ctDNA Tool for Identifying ESR1-Mutated Biology in ESR1-non-Mutated Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (MBC)**
Isabel Garcia Fructuoso, IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
- 12:00 - 12:00 **50P - Circulating cytokines to predict pCR to neoadjuvant chemotherapy and nivolumab for ER+/HER2- BC: analysis of the phase 2 GIADA trial**
Maria Vittoria Dieci, University of Padova, Padova, Italy
- 12:00 - 12:00 **51P - ctDNA analyses at baseline in patients with ER-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC) treated with imlunestran in the EMBER phase I study.**
Karthik Giridhar, Mayo Clinic - Rochester, Rochester, United States of America
- 12:00 - 12:00 **52P - Comparing the genomic landscape of de novo vs recurrent metastatic breast cancer by ctDNA and tissue profiling**
Federica Giugliano, Institut Gustave Roussy, Villejuif, France
- 12:00 - 12:00 **53P - Longitudinal ctDNA Surveillance in Older Women With ER+ Breast Cancer**



Who Omit Surgery and Receive Primary Endocrine Therapy

Steffi Oesterreich, UPMC Hillman Cancer Center, Pittsburgh, United States of America

- 12:00 - 12:00 **54P - Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment**
Eva Valentina Klocker, Medical University of Graz, Graz, Austria
- 12:00 - 12:00 **55P - Landscape of PIK3CA, PTEN, and AKT1 alterations in advanced breast cancer (ABC) using circulating tumor DNA (ctDNA) Next Generation Sequencing (NGS) in Asia and the Middle East (AME)**
Shaheenah Dawood, Mediclinic City Hospital, Dubai, United Arab Emirates
- 12:00 - 12:00 **56P - Longitudinal circulating plasma protein immune profiling reveals biomarkers of treatment response to neoadjuvant trastuzumab-emtansine (T-DM1) in early HER2-positive breast cancer: a secondary analysis of the phase II PREDIX HER2 trial**
I. Zerdes, Karolinska Institutet, Stockholm, Sweden
- 12:00 - 12:00 **57P - Intrinsic and acquired blood-based tumor mutational burden in metastatic ER+/HER2- breast cancer treated with endocrine therapy and a CDK4/6-inhibitor**
Mitchell Elliott, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada
- 12:00 - 12:00 **58P - Soluble immune checkpoints as a promising avenue for breast cancer stratified by molecular subtype**
Banu Yigit, Bagcilar Training and Research Hospital, Istanbul, Turkey
- 12:00 - 12:00 **59P - Potential of AKT1, ERBB2, ESR1, KRAS, PIK3CA and TP53 alterations detected by a new NGS assay on liquid biopsy predictive of early response/resistance to hormonal therapy and CDK4/6 inhibitors.**
Sara Bravaccini, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
- 12:00 - 12:00 **60P - Expression of antibody-drug conjugate targets in metastatic breast cancer**
Kristien Borremans, KU Leuven, Leuven, Belgium
- 12:00 - 12:00 **61P - In-situ Generation of Cancer Antigens with ProLonged TLR7/8 Agonist Immunomodulator for Cancer Therapy in Preclinical Model**
Chul Kim, Progeneer Inc., Seoul, Korea, Republic of
- 12:00 - 12:00 **62P - Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort**
Gudbjörg Sigurjonsdottir, Department of Clinical Sciences, Lund University, Lund, Sweden
- 12:00 - 12:00 **63P - Enhancing HER2 Evaluation: Correlation between APIS Breast Cancer Subtyping Kit and IHC/ISH for Accurate HER2 Quantification**



Joanna Gorniak, Apis Assay Technologies Ltd, Manchester, United Kingdom

- 12:00 - 12:00 **65P - Multi-site European Study of a Fully Automated Artificial Intelligence Solution for HER2 IHC Scoring in Breast Cancer**
Joanna Cyrta, Institut Curie, Paris, France
- 12:00 - 12:00 **66P - Evaluation of an artificial intelligence algorithm for automated PD-L1 CPS scoring in triple-negative breast cancer across institutions, scanners, and antibody clones.**
Patrick Frey, Mindpeak GmbH, Hamburg, Germany
- 12:00 - 12:00 **67P - Artificial Intelligence to predict early progressors among aBC patients treated with first-line CDK4/6i: a sub-analysis from PALMARES-2 study**
Leonardo Provenzano, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, MAGLIE, Italy
- 12:00 - 12:00 **68P - Application of a Machine Learning Model for Identifying an Ultra-low Risk Group of Early Breast Cancer Patients**
Michail Sarafidis, Karolinska Institutet, Stockholm, Sweden
- 12:00 - 12:00 **69P - Deep learning prognostication through prediction of TP53 gene mutation status on breast cancer hematoxylin and eosin slides**
Nikos Tsiknakis, Karolinska Institutet, Stockholm, Sweden
- 12:00 - 12:00 **70P - Development and Validation of a Machine Learning (ML) Nomogram to Predict RSCLin Results and Guide Adjuvant Treatment of Node-negative (N0) Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor Negative (HER2-) Early Breast Cancer (eBC) in Europe.**
Flavia Jacobs, IRCCS Humanitas Research Hospital, Rozzano, Italy
- 12:00 - 12:00 **71P - Patient-reported understanding of biomarkers associated with metastatic breast cancer (mBC) diagnosis: results from a global mBC survey in 36 countries**
Eva Schumacher-Wulf, Brustkrebsmagazin, Köln, Germany
- 12:00 - 12:00 **72P - A Cost-Consequence Model Assessing Gene Expression Tests Among Early-Stage Breast Cancer Patients in Belgium**
Caroline Charles, CHU de Montpellier - Hopital Gui de Chauliac, Montpellier, Cedex, France
- 12:00 - 12:00 **73P - Real world analysis of the use of the 21-gene assay in prognostically intermediate luminal breast cancer (BC): experience from a French multicenter cohort**
Bruno Cutuli, Centre ICONE, Bezannes, France
- 12:00 - 12:00 **74P - Assessing the Implementation of the HER2DX Genomic Test in a Real-World Setting for HER2-Positive Breast Cancer**
Juan Miguel Cejalvo, Hospital Clinico Universitario de Valencia, Valencia, Spain



- 12:00 - 12:00 **75P - A multicenter physician survey evaluating Ki-67 use in breast cancer management in Canada**
Jennifer Leigh, The Ottawa Hospital Regional Cancer Centre, Ottawa, Canada
- 12:00 - 12:00 **76P - Pegylated Immunoliposome encapsulating docetaxel: In Vitro Activity and Optimal Pharmacokinetics in a breast cancer model**
Mathilde Dacos, Aix Marseille University, Marseille, Cedex, France
- 12:00 - 12:00 **77P - Breast cancer pharmacogenetics in Botswana**
Keneuoe Nthontho, University of Botswana, Gaborone, Botswana
- 12:00 - 12:00 **78P - Tumor educated platelets promote disease advancement in breast cancer by interacting with cancer stem cells**
Aishwarya Guha, CNCI - Chittaranja National Cancer Institute, Kolkata, India
- 12:00 - 12:00 **79P - 3D Matrix Models and Multi-Organ Chip platform for advancing the investigation of breast cancer dynamics and Bone Metastasis in vitro**
Silvia Scaglione, National Research of Council, genoa, Italy
- 12:00 - 12:00 **80P - Is there a link between crown-like structures and tumour-associated macrophages in patients with HER2+ breast cancer?**
Sophie Raffray, University of Southampton, Southampton, United Kingdom
- 12:00 - 12:00 **81P - Exosomal HMGB1 induce PD-L1+-tumor associated macrophages via glycometabolic reprogramming to promote lung-tropic metastasis of triple negative breast cancer**
Wei-Xian Chen, The Affiliated Changzhou Second People's Hospital of Nanjing Medical University, Changzhou, China
- 12:00 - 12:00 **82P - VRTX531, a Potent Inhibitor of USP1 for Treatment of BRAC1/2mut and HRD+ cancers**
Uday Surampudi, VRise Therapeutics Inc., Cambridge, United States of America
- 12:00 - 12:00 **83P - Boron-doped alginate carbon-nanogels exhibits superior anti-metastatic effect on breast cancer by cell cycle arrest and actin dysfunction**
Saumyadip Sarkar, National Taiwan Ocean University, Keelung City, Taiwan
- 12:00 - 12:00 **84P - Investigating the Activation of Brain-derived Neurotrophic Factor (BDNF)-Tropomyosin receptor kinase B (TrkB) Pathway in Breast Cancer Brain Metastasis**
Jieun Lee, The Catholic University of Korea - Seoul St.Mary Hospital, Seoul, Korea, Republic of
- 12:00 - 12:00 **85P - Is omitting axillary lymph node dissection applicable to all Z0011-eligible breast cancer patients?**
Xinyu Li, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China



- 12:00 - 12:00 **86P - The value of intraoperative frozen section examination in the survival of breast cancer**
Anne W. Zhu, Medical University of Vienna, Vienna, Austria
- 12:00 - 12:00 **87P - Locoregional response and type of axillary surgery in patients who received neoadjuvant systemic therapy (NST): A Retrospective multicenter analysis of 720 patients**
Vesna Bjelic-Radisic, Helios University Hospital Wuppertal University Witten /Herdecke, Wuppertal, Germany
- 12:00 - 12:00 **88P - Bilateral Mastectomy and Breast Cancer Mortality**
Vasily Giannakeas, Women's College Hospital, Toronto, Canada
- 12:00 - 12:00 **89P - BIMAP: Breast cancer Intra-operative Margin Assessment using PET-CT**
Anne-Sofie De Crem, UZ Gent - University Hospital Ghent, Gent, Belgium
- 12:00 - 12:00 **90P - Where is the Balance of Benefit: Blue Dye Anaphylaxis Versus Sentinel Node Understaging?**
Danayan Luxmanan, Southampton General Hospital, Southampton, United Kingdom
- 12:00 - 12:00 **92P - Sentinel Lymph Node Biopsy for Local Recurrence of Breast Cancer**
Elizaveta Golovina, First Moscow State Medical University named after I.M. Sechenov (Sechenov Universaty), Moscow, Russian Federation
- 12:00 - 12:00 **93P - Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world study**
Wenhui Guo, Fujian Medical University Union Hospital, Fuzhou, China
- 12:00 - 12:00 **94P - Biological Effects of a Pre-Operative Radiotherapy Boost in Early-Stage Breast Cancer: Primary Results of the YOUNGSTER Unicentric Single-Arm Clinical Trial**
Fara Brasó-Maristany, IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
- 12:00 - 12:00 **95P - Omission of postoperative radiation therapy in older patients with low-risk breast cancer treated with breast-conserving surgery: long-term results of the KohoRT study**
Sofia Palmér, Örebro University Hospital, Örebro University, Örebro, Sweden
- 12:00 - 12:00 **96P - Intraoperative radiological control of resection margins after neoadjuvant systemic therapy in breast-conserving surgery in patients with breast cancer**
Yana Bondarchuk, N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation
- 12:00 - 12:00 **97P - The impact of updated imaging software on the performance of machine**



learning models for breast cancer diagnosis. A multi-center, retrospective study

Lie Cai, University Hospital Heidelberg, Heidelberg, Germany

- 12:00 - 12:00 **98P - The added value of whole-body diffusion weighted MRI (WB-DWI/MRI) in staging invasive lobular carcinoma**
Karen Van Baelen, KU Leuven, Leuven, Belgium
- 12:00 - 12:00 **99P - Development of a Risk Assessment and Prediction Model for DCIS Recurrence: Insights from Analysis of 600 Patients**
Warachya Arjhan, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand
- 12:00 - 12:00 **100P - Diagnostic value of CT-scan and ultrasound for axillary lymph node staging in early breast cancer**
Tetiana Shevchuk, Verum Expert Clinic, Kyiv, Ukraine
- 12:00 - 12:00 **101P - Correlation of Radiological and Pathologic Lymph Nodes Status After Neoadjuvant Treatment of Early HER2-positive Breast Cancer**
Alexander Petrovsky, National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, Russian Federation
- 12:00 - 12:00 **102P - The impact of multiparametric whole-body magnetic resonance imaging on Breast Cancer management: a prospective study**
Filippo Merloni, IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, Italy
- 12:00 - 12:00 **103P - PET-CT in localized breast cancer: Does it impact on the therapeutic decision?**
Paula Macias Rodriguez, Hospital Universitario Virgen del Rocio, Seville, Spain
- 12:00 - 12:00 **104P - Quantification Analysis of Low-Cost Near Infrared Camera for Breast Cancer Treatment-Related Lymphedema Fluorescence Imaging**
Bayu Brahma, Dharmais National Cancer Hospital, West Jakarta, Indonesia
- 12:00 - 12:00 **105P - Impact of the number of synchronous cancer lesions in Bulgarian patients with multiple breast cancer**
Slavyana Usheva, University Hospital Tsaritsa Yoanna ISUL, Sofia, Bulgaria
- 12:00 - 12:00 **106P - Incorporating Religious and Cultural Background: Patient Informed Consent in the Era of Acellular Dermal Matrix Breast Reconstruction**
Jose A. Foppiani, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA, Boston, United States of America
- 12:00 - 12:00 **107P - Clinicopathologic Features of Breast Cancer Patients in a Single Tertiary Hospital in the Philippines**
Maria Carmela Vistal, St. Luke's Medical Center - Quezon City, Quezon City, Philippines



- 12:00 - 12:00 **108TiP - CINDERELLA Clinical Trial (NCT05196269): using artificial intelligence-driven healthcare to enhance breast cancer locoregional treatment decisions**
Andre Pfob, Heidelberg University Hospital, Heidelberg, Germany
- 12:00 - 12:00 **114P - Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus chemotherapy in HER2-positive early breast cancer (EBC): Long-term efficacy and safety analysis of the randomised, open-label, multicentre Phase III (neo)adjuvant FeDeriCa study**
Christian Jackisch, Sana Klinikum Offenbach, Offenbach, Germany
- 12:00 - 12:00 **115P - Neoadjuvant pyrotinib combined with trastuzumab, albumin paclitaxel, and carboplatin for HER2-positive early or locally advanced breast cancer: a single-arm phase II trial**
Mei Liu, Chongqing University Cancer Hospital, Chongqing, China
- 12:00 - 12:00 **116P - Interim analysis of 300 patients with HER2+/HR+ early breast cancer enrolled in the multi-national, prospective, observational ELEANOR NIS treated with extended adjuvant neratinib in clinical routine**
Rupert Bartsch, Medizinische Universitaet Wien, Vienna, Austria
- 12:00 - 12:00 **117P - Three-year invasive disease-free survival results from a phase 2 study of pyrotinib plus trastuzumab and albumin-bound paclitaxel as neoadjuvant treatment in HER2-positive early or locally advanced breast cancer**
Dan Zheng, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, China
- 12:00 - 12:00 **118P - A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in Human Epidermal Growth Factor Receptor 2 positive (HER2+) early breast cancer in China: NER-Tree study—An interim analysis on patient characteristics and pretreatment patterns**
Jin Zhang, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China
- 12:00 - 12:00 **119P - HER2+ early-stage breast cancer treated with extended adjuvant neratinib in the context of the European Early Access Program: NEAR study final results**
Tajana Silovski, KBC - University Hospital Centre Zagreb, Zagreb, Croatia
- 12:00 - 12:00 **120P - Impact of PET-CT and neoadjuvant systemic treatment in patients with stage I HER2+ breast cancer**
Josefien Van Olmen, Netherlands Cancer Institute, Amsterdam, Netherlands
- 12:00 - 12:00 **121P - Endocrine response assessment in HR+ HER2- early breast cancer: Concordance of central versus local Ki67 measurements in the ADAPTcycle trial**
Moritz Hamann, Rotkreuzklinikum München - Frauenklinik, Munich, Germany
- 12:00 - 12:00 **122P - Primary results and biomarker analysis from PREDIX Lum B, a prospective randomized phase 2 trial investigating sequence of neoadjuvant chemotherapy and palbociclib/endocrine therapy for luminal breast cancer**



Alexios Matikas, Karolinska Institutet, Stockholm, Sweden

- 12:00 - 12:00 **123P - Goserelin 10.8 mg and 3.6 mg Depots in Breast Cancer (BC): A Large Real-World Noninferiority Study**
Yongsheng Wang, Shandong Cancer Hospital and Institute, Jinan, China
- 12:00 - 12:00 **124P - Neoadjuvant Durvalumab plus Endocrine Therapy following Immunoattractant Exposure for early-stage ER+/HER2- breast cancer**
Benjamin Verret, Institut Gustave Roussy, Villejuif, France
- 12:00 - 12:00 **125P - Suboptimal ovarian suppression during adjuvant endocrine therapy for premenopausal women with breast cancer: an exploratory analysis of the PREFER and GIM 23 studies**
Simone Nardin, Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy, Genova, Italy
- 12:00 - 12:00 **126P - A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥ 70 with lower risk breast cancer (BC) [REaCT-70 Study].**
Marie-France Savard, The Ottawa Hospital Cancer Centre, Ottawa, Canada
- 12:00 - 12:00 **127P - Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial**
Jens Huober, Breast Center St. Gallen, Cantonal Hospital, St. Gallen, Switzerland
- 12:00 - 12:00 **129P - Adherence to Adjuvant Endocrine Therapy in the Era of Combination Treatments - a Population-Based Study**
Louise Eriksson Bergman, Karolinska Institutet, Stockholm, Sweden
- 12:00 - 12:00 **130P - Progesterone receptor (PR) status and survival outcomes of ER-negative breast cancer: a population-based cohort study**
Ly Wenjie, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
- 12:00 - 12:00 **131P - Efficacy and Safety of Different Dosage Forms of Gonadotropin Releasing Hormone Agonists Combined with Selective Estrogen Receptor Modulators or Aromatase Inhibitors in Premenopausal Hormone Receptor-Positive Breast Cancer Patients**
Jinna Lin, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
- 12:00 - 12:00 **132P - Clinico-pathological characteristics, treatments and survival outcomes of patients with high-risk hormone receptor positive early breast cancer (HR+ BC) in French Real World (RW) setting: a study from CANTO cohort**
Federica Giugliano, Institut Gustave Roussy, Villejuif, France



- 12:00 - 12:00 **133P - Clinico-pathological predictors of outcome in the (neo)adjuvant setting of luminal/HER2-negative Invasive Lobular breast Cancer (ILC)**
Luisa Carbognin, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 12:00 - 12:00 **134P - Pathologic complete response according to the level of tumor-infiltrating lymphocytes and histologic grade in HR+HER2- breast cancer**
Seung Ho Baek, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
- 12:00 - 12:00 **135P - Characteristics and Dosing Patterns of US Patients Diagnosed with HR+/HER2- Early Breast Cancer Initiating Abemaciclib at a Lower Dose than the Approved 150mg BID**
Laura Spring, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States of America
- 12:00 - 12:00 **136P - Impact of Ovarian Stimulation on Breast Tumor Biology: First Results from a Pilot Study**
Yasmina Barral El Gaoui, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
- 12:00 - 12:00 **137P - Adherence to and optimization of guidelines for Risk of Recurrence/Prosigna testing using a machine learning model: a Swedish multicenter study**
Una Kjällquist, Karolinska Institute, Solna, Sweden
- 12:00 - 12:00 **138P - Predicted cumulative risk of late relapse in HR-positive/HER2-negative BC: a competing risk analysis of a real-world population.**
Grazia Vernaci, IOV - Istituto Oncologico Veneto IRCCS, Padova, Italy
- 12:00 - 12:00 **139P - Acceptance to Extend Hormonal Treatment Among Young Egyptian Breast Cancer Patients: A Questionnaire-Based Cross-Sectional Study.**
Omnia Korani, National Cancer Institute - Cairo University, Cairo, Egypt
- 12:00 - 12:00 **140P - Use of Chemotherapy and Loco-regional Therapy for Stage IA triple-negative Breast Cancer and their Association with Oncologic Outcomes: A Cancer Registry Study**
Andre Pfob, University Hospital Heidelberg, Heidelberg, Germany
- 12:00 - 12:00 **141P - The Causes and Consequences of Incomplete Paclitaxel Administration during the Neoadjuvant treatment of Early Triple negative and HER2 positive breast cancer (CIPNETH)**
Cedric Van Marcke, Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium
- 12:00 - 12:00 **142P - Exploring 18F-FDG PET as a predictor of immune-related adverse events (irAEs) in early stage triple negative breast cancer (eTNBC)**
Alessia Lucia Daverio, Institut Gustave Roussy, Villejuif, Cedex, France
- 12:00 - 12:00 **143P - Sociodemographic Factors Associated with Adjuvant Chemotherapy**



Receipt in Stage I Triple Negative Breast Cancer (TNBC)

Candice Thompson, Stanford University, Stanford, United States of America

- 12:00 - 12:00 **144P - Factors affecting long term outcomes in patients with pathologic complete response after neoadjuvant chemotherapy for early breast cancer: a population-based study**
Caroline Boman, Karolinska Institutet, Solna, Sweden
- 12:00 - 12:00 **145P - Impact of immunotherapy addition to dose density of neoadjuvant chemotherapy for triple negative breast cancer: a retrospective, real-world study from multiple centres in London, UK**
Mesel Veli, UCLH - University College London Hospitals NHS Foundation Trust, London, United Kingdom
- 12:00 - 12:00 **146P - Long-term outcomes of patients with triple negative breast cancer treated with adjuvant dose-dense sequential chemotherapy (ddsc): a Hellenic Cooperative Oncology Group (HeCOG) study**
Elena Fountzilas, Hellenic Cooperative Oncology Group, Athens, Greece
- 12:00 - 12:00 **147P - Racial bias in pretreatment MRI radiomics features to predict response to neoadjuvant systemic treatment in breast cancer. A Multicenter study in China, Germany, and the US**
Lie Cai, University Hospital Heidelberg, Heidelberg, Germany
- 12:00 - 12:00 **148P - The impact of chemotherapy relative dose intensity on pathological complete response and event-free survival in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.**
Roberto Buonaiuto, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
- 12:00 - 12:00 **149P - Risk of type 2 diabetes after breast cancer treatment: a 26-year population-based cohort study**
Kasper Kjærsgaard, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark
- 12:00 - 12:00 **150P - Diagnostic accuracy of MRI in tumour response evaluation after neoadjuvant chemotherapy in patients with different subtypes of breast cancer**
Lucia Vanovcanova, Sr.Elizabeth Cancer Centre, Bratislava, Slovak Republic
- 12:00 - 12:00 **151P - Exploring the Predictive Potential of [18F]FDG PET/CT for Pathological Complete Response to Neoadjuvant Therapy: A Prospective Study**
Fabrizia Gelardi, UniSR - Università Vita e Salute San Raffaele Milano, Milan, Italy
- 12:00 - 12:00 **152P - Inflammatory BREast cancer (IBC) in low and mIDDLE-income countries (LMICs): knowledGE, and practice patternS, The BRIDGES study**
Ilana Schlam, Tufts Medical Center, Boston, United States of America
- 12:00 - 12:00 **153P - Correlation Between Disease Free Survival (DFS) Endpoints and Overall Survival (OS) in Elderly Patients with Human Epidermal Growth Factor Receptor**



2-Negative (HER2-) Early Breast Cancer (eBC)

Mark Robson, Memorial Sloan Kettering Cancer Center, New York, United States of America

- 12:00 - 12:00 **154P - Validation of PREDICT tool version 2.2 in early-stage breast cancer (BC) patients enrolled in adjuvant trials by the Gruppo Italiano Mammella (GIM) and Mammella Intergruppo (MIG)**
Roberto Borea, IRCCS Ospedale Policlinico San Martino, Genova, Italy
- 12:00 - 12:00 **155P - From Bench to Equity: Closing the Knowledge Gap on Racial Differences in TNBC Response to Immunotherapy**
Oday Elmanaseer, Georgetown University Medical Center, Washington, United States of America
- 12:00 - 12:00 **156P - The impact of Ki-67 on prognosis and chemotherapy benefit in breast cancer patients with ER-positive/HER2-negative micrometastatic disease in sentinel lymph nodes: a register-based cohort study.**
Eva Tegnelyus, Örebro University Hospital, Örebro University, Örebro, Sweden
- 12:00 - 12:00 **157TiP - A Window-of-Opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC) (IBCSG 67-22; PREcoopERA)**
Elisabetta Munzone, IEO - Istituto Europeo di Oncologia, Milan, Italy
- 12:00 - 12:00 **158TiP - NEOadjuvant Abemaciclib and Giredestrant trial in patients with ER-positive, HER2-negative Early breast cancer (GIM31-Neo-AGILE trial)**
Claudia Von Arx, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, Italy
- 12:00 - 12:00 **159TiP - TROPION-Breast04: Phase (Ph) 3 study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (D) followed by adjuvant (adj) D vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2- breast cancer (BC)**
Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany
- 12:00 - 12:00 **160P - Characteristics and outcomes of young breast cancer patients harboring BRCA pathogenic variants according to histologic subtype**
Elisa Agostinetti, Institute Jules Bordet, Bruxelles, Belgium
- 12:00 - 12:00 **161P - Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families.**
Maartje Schreurs, Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, Netherlands
- 12:00 - 12:00 **162P - The influence of BRCA1 large genomic rearrangements on the clinicopathological features and survival of patients with breast cancer**
Alejandro Aranda-Gutierrez, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico



- 12:00 - 12:00 **163P - Characterization of HER2-Low Breast Cancer in Young Women with Germline BRCA1/2 Pathogenetic Variants: Results of a Large International Retrospective Cohort Study**
Francesco Schettini, IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
- 12:00 - 12:00 **164P - Incorporation of the Polygenic Risk Score (PRS) in breast cancer (BC) risk estimation among carriers of a Moderate Penetrance Pathogenetic Variant (MPPV)**
Maria Rezaqallah Aron, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 12:00 - 12:00 **165P - From Bench to Bedside: Functional Domains of BRCA Mutations for Personalized Medicine in Breast Cancer**
Pablo Torres-Mozas, Hospital Universitario de Jaén, Jaén, Spain
- 12:00 - 12:00 **166P - Clinical use of tumor sequencing for identification of germline pathogenetic variants (gPV) in breast cancer (BC): the SEQ project**
Mara Cruellas Lapena, Hospital Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 12:00 - 12:00 **167P - Exploring the role of rare germline variants in non-coding regions of cancer predisposition genes in triple-negative breast cancer patients**
Michela Palleschi, IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, Italy
- 12:00 - 12:00 **168P - Cardiovascular Risks in Breast Cancer: Insights from BRCA1/2 Mutation Carriers and Sporadic Cases**
Panagiotis Mallios, Linköping University, Norrköping, Sweden, Norrköping, Sweden
- 12:00 - 12:00 **169P - Radiomics Models for B-mode Breast Ultrasound and Strain Elastography for Breast Cancer Diagnosis (INSPIRED 005): An International, Multicenter Analysis**
Tanja He, Universitätsfrauenklinik Heidelberg, Heidelberg, Germany
- 12:00 - 12:00 **170P - Clinico-pathological profile of women with breast arterial calcification on mammograms - Retrospective analysis of cardiac risk and malignant transformation**
Simran Razdan, Continental Hospitals Ltd., Hyderabad, India
- 12:00 - 12:00 **171P - A deep learning model for breast cancer diagnosis from fine-needle aspiration cytology whole slide images**
Loïc Le Bescond, CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, France
- 12:00 - 12:00 **172P - MicroRNAs in nipple aspirate fluid hold promise as a novel screening diagnostic for early breast cancer detection: results from a Dutch multicenter cross-sectional study**
Laura De Rooij, UMC - University Medical Center Utrecht, Utrecht, Netherlands



- 12:00 - 12:00 **173P - Clinical Utility of piezoelectricity hand-held scanner towards breast texture changes and early tumor detection**
Joana Gonçalves, Hospital Nossa Senhora do Rosário (Centro Hospitalar Barreiro Montijo, EPE), Barreiro, Portugal
- 12:00 - 12:00 **174P - Modelling Cost-Effectiveness of breast cancer screening: Mammography leads to substantial cost savings for breast cancer treatment**
Moira Rushton, University of Ottawa Faculty of Medicine, Ottawa, Canada
- 12:00 - 12:00 **175P - Global burden, trends and risk factors of premenopausal breast cancer from 1990 to 2019 with prediction until 2039**
Cao Kun, Fujian Medical University - Qishan Campus, Fuzhou, China
- 12:00 - 12:00 **176P - Age-adjusted trends of malignant breast hemangiosarcoma**
Amr Aly, Suez Canal University Hospital, Ismailia, Egypt
- 12:00 - 12:00 **177P - Results Of The Recent Nationwide Breast Cancer Screening In CAMEROON**
Blaise Nkegoum, UNIVERSITY HOSPITAL CENTER, YAOUNDE, Cameroon
- 12:00 - 12:00 **178TiP - The BRAVE study: a web-based prospective cohort and biological bank for unaffected BRCA1/2 Mutation Carriers**
Eleonora Bruno, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy
- 12:00 - 12:00 **185P - Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)**
Komal Jhaveri, Memorial Sloan Kettering Cancer Center, New York, United States of America
- 12:00 - 12:00 **186P - Exploratory Pooled Safety Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients With HER2+ or HER2-low Unresectable and/or Metastatic Breast Cancer (mBC) in DESTINY-Breast Trials**
Yeon Hee Park, Samsung Medical Center, Seoul, Korea, Republic of
- 12:00 - 12:00 **187P - Stage I results of a phase II study of datopotamab deruxtecan (Dato-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)**
Rupert Bartsch, Medical University of Vienna, Vienna, Austria
- 12:00 - 12:00 **188P - A Health-Related Quality-of-Life (HRQoL) Analysis From DESTINY-Breast04: Trastuzumab Deruxtecan (T-DXd) vs Capecitabine (CAP) in Patients (Pts) With Hormone Receptor-Positive (HR+), HER2-Low Metastatic Breast Cancer (mBC)**
Naoto Ueno, University of Hawai'i Cancer Center, Honolulu, United States of America
- 12:00 - 12:00 **189P - The impact of high body mass index (BMI) on the safety and efficacy of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative**



breast cancer (mTNBC) from ASCENT

Laura García Estevez, MD Anderson Cancer Center Madrid, Madrid, Spain

- 12:00 - 12:00 **190P - French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients (pts) with HER2+ metastatic or unresectable breast cancer (m/u BC): first results of REALITY-01 ambispective study**
Jean-Yves Pierga, Institut Curie, Paris, France
- 12:00 - 12:00 **191P - Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study**
Nadia Haddy, EPI-PHARE, Saint-Denis Cedex, France
- 12:00 - 12:00 **192P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic HER2-positive breast cancer**
Luca Visani, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
- 12:00 - 12:00 **193P - Efficacy of sacituzumab govitecan versus treatment of physician's choice in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: A meta-analysis of TROPiCS-02 and EVER-132-002 trials**
Oleg Gluz, Breast Center Niederrhein, Evangelical Hospital Johanniter Bethesda, Mönchengladbach, Germany
- 12:00 - 12:00 **194P - Monitoring for pneumonitis due to trastuzumab deruxtecan (T-DXd); a single centre experience**
Olivia Walker, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, United Kingdom
- 12:00 - 12:00 **195P - Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with HER2 positive advanced breast cancer: a multicentric Portuguese study**
Rita Bizarro, Hospital Beatriz Angelo - SNS, Loures, Portugal
- 12:00 - 12:00 **196P - Surgical axillary intervention after neoadjuvant systemic therapy (NST) for early-stage breast cancer - Clinical significance of micrometastases: data from five neoadjuvant studies**
Fabienne Warnecke, University Hospital, Goethe University Frankfurt,, Frankfurt am Main, Germany
- 12:00 - 12:00 **197P - Malignant Pleural Effusion derived metastatic breast cancer cells as an ex vivo model for personalized drug response**
Zhanna Dauyey, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
- 12:00 - 12:00 **198P - Pembrolizumab Plus Olaparib vs Pembrolizumab Plus Chemotherapy After Induction With Pembrolizumab Plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Patient-Reported Outcomes From KEYLYNK-009**
Antonio Llombart Cussac, Hospital Arnau de Vilanova, Valencia, Spain



- 12:00 - 12:00 **199P - Adoptive PD1+ Tumor-Infiltrating Lymphocyte Therapy for Metastatic TNBC: First Results of the Safety Run-in Phase of the TILS001 Clinical Trial**
Laura Angelats, Hospital Clinic y Provincial de Barcelona / August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
- 12:00 - 12:00 **200P - Testing a higher dose (90 mg s.c.) of efitlagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003**
Serafin Morales Murillo, Hospital Arnau de Vilanova - Lleida, Alpicat, Spain
- 12:00 - 12:00 **201P - The implementation of first-line pertuzumab and the impact on overall survival in patients with de Novo HER2+ metastatic breast cancer in the Netherlands in 2008-2017: a population-based cohort study**
Nan Ding, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
- 12:00 - 12:00 **202P - Complete response rates, treatment patterns and survival outcomes in patients treated with first-line pertuzumab-based therapy in HER2-positive advanced breast cancer: a SONABRE study**
Nan Ding, Maastricht University Medical Center (MUMC), Maastricht, Netherlands
- 12:00 - 12:00 **203P - Real-world treatment patterns in patients with HER2+ unresectable (u) or metastatic (m) breast cancer (BC): HER2 Real study final analysis in Asia-Pacific (APAC) and Brazil**
Carlos Barrios, Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil
- 12:00 - 12:00 **204P - Clinical features predictive of never-progressive disease to first-line anti-HER2 therapy: real-world data from the ESME national cohort**
Thomas Grinda, Institut Gustave Roussy, Villejuif, Cedex, France
- 12:00 - 12:00 **205P - Trastuzumab biosimilar (TB) in combination with pertuzumab (P) and chemotherapy (CT) in Her2 positive, metastatic breast cancer (MBC) : efficacy and safety.**
Gilles Freyer, Lyon Sud Hospital Center - HCL, Pierre Benite, France
- 12:00 - 12:00 **206P - Prognostic role of tumor-infiltrating lymphocytes (TILs) in first-line HER2-positive (HER2+) metastatic breast cancer (BC): a real-world study**
Beatrice Taurelli Salimbeni, European Institute of Oncology IRCCS, Milan, Italy
- 12:00 - 12:00 **207P - Sequential therapy with HER2 tyrosine kinase inhibitors in patients with HER2-positive metastatic breast cancer**
Elena Shagisultanova, University of Colorado Cancer Center - Anschutz Medical Campus, Aurora, United States of America
- 12:00 - 12:00 **208P - Clinicopathological factors and treatment management in HER2+ breast cancer patients with central nervous system metastasis**
Ornella Ponzoni, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, Italy
- 12:00 - 12:00



209P - Real-world effectiveness of palbociclib + endocrine therapy in HR+/HER2- Advanced Breast Cancer patients: Interim Results of the PERFORM study

Matthias Korell, Johanna Etienne Krankenhaus, Neuss, Germany

12:00 - 12:00 **210P - Prognostic value of HER2-low status in metastatic breast cancer (mBC) patients treated with I line CDK 4/6 inhibitors (CDK 4/6i): a real-word analysis of the GIM14/BIOMETA study**

Chiara Molinelli, IRCCS Ospedale Policlinico San Martino, Genova, Italy

12:00 - 12:00 **211P - Drug-drug Interactions and their impact on clinical outcomes and adverse events in hormone receptor (HR)+/HER2- advanced breast cancer patients treated with ribociclib + letrozole: Insights from the BiotaLEE Trial**

Andrea Botticelli, Sapienza University of Rome, Roma, Rome, Italy

12:00 - 12:00 **212P - A Phase 1b/2 study of palazestrant (OP-1250) in combination with ribociclib in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer**

Virginia Borges, UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, United States of America

12:00 - 12:00 **213P - Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC).**

Stefania Morganti, Dana Farber Cancer Institute, Boston, United States of America

12:00 - 12:00 **214P - Comparing Ribociclib versus Palbociclib as a second line treatment in combination with Fulvestrant in metastatic breast cancer. A randomised clinical trial.**

Manar Hamed, Mansoura University - Faculty of Medicine, elmahalla elkobra, Egypt

12:00 - 12:00 **215P - Impact of germline BRCA1/2 pathogenic variants on outcomes of HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: a systematic review and meta-analysis**

Michele Bottosso, University of Padua, Padova, Italy

12:00 - 12:00 **216P - What is driving treatment decision following 1st line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine?: Real-world data from the RIBANNA study (6th interim analysis (IA))**

Diana Lüftner, Immanuel Campus Rüdersdorf, Medical University of Brandenburg Theodor Fontane, Rüdersdorf bei Berlin, Germany

12:00 - 12:00 **217P - Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced unacceptable toxicity**

Chiara Benvenuti, Institut Gustave Roussy, Villejuif, Cedex, France

12:00 - 12:00 **218P - Vepdegestrant, a PROteolysis TARgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b**



cohort results

Erika Hamilton, Sarah Cannon Research Institute, Nashville, United States of America

12:00 - 12:00

219P - New prognostic factors in advanced HR+ HER2- breast cancer treated with CDK4/6 inhibitors

Sonia Crocetti, Macerata Hospital, Macerata, Italy

12:00 - 12:00

220P - Impact of time to progression (TTP) on CDK4/6 inhibitor (CDK4/6i) therapy on progression-free survival (PFS) in HR+/HER2-/PIK3CA-mutated advanced breast cancer (ABC) patients (pts) treated with alpelisib plus endocrine therapy (ALP+ET): An exploratory analysis of the METALLICA trial

Antonio Llombart-Cussarc, Hospital Arnau de Vilanova, Valencia, Spain

12:00 - 12:00

221P - Incidence and survival after brain metastases among patients with stage I-III breast cancer: A population-based study

Rania Chehade, University of Toronto - St. George Campus, Toronto, Canada

12:00 - 12:00

222P - Poor response to Cyclin Dependent Kinase 4/6 inhibition in metastatic inflammatory breast cancer

Azadeh Nasrazadani, MD Anderson Cancer Center, Houston, United States of America

12:00 - 12:00

223P - Real-world treatment efficacy of ribociclib or palbociclib plus fulvestrant in hormone receptor-positive/HER2-negative metastatic breast cancer: Turkish Oncology Group (TOG) Study

Seda Kahraman, Ankara Yildirim Beyazit Universty - Faculty of Medicine, ankara, Turkey

12:00 - 12:00

224P - Efficacy of Single-Agent Second Line Fulvestrant (FUL) in Metastatic Invasive Lobular Carcinoma (mILC) Exposed to First Line Aromatase Inhibitors (AI) and Cyclin-Dependent Kinase 4 and 6 inhibitors (CDK4/6is).

Jason Mouabbi, MD Anderson Cancer Center, Houston, United States of America

12:00 - 12:00

225P - Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients

María Luisa Sánchez-León, Hospital Universitario Virgen Macarena, Seville, Spain

12:00 - 12:00

226P - Prevalence and Characteristics of HR+/HER2- MBC with ESR1 Mutations Post-CDK Inhibitor Therapy

Roberta Scafetta, Policlinico Universitario Campus Bio-Medico, Roma, Italy

12:00 - 12:00

227P - The role of CDK4/6 inhibitors in sequencing of endocrine treatment in metastatic breast cancer or can we accept the SONIA trial results in real-world practice?

Olesya Stativko, Moscow City Clinical Oncological Hospital No. 1, Moscow, Russian Federation

12:00 - 12:00

228P - Comparison of Response with Chemotherapy vs Endocrine Therapy and its Association with Ki67 in Hormone Receptor Positive Metastatic Breast Cancer



Sundas Rafique, King Edward Medical University, Lahore, Pakistan

- 12:00 - 12:00 **229P - The influence of ethnicity on cyclin-dependent kinase inhibitors efficacy: a systematic review and meta-analysis**
Roberto Buonaiuto, Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
- 12:00 - 12:00 **230P - HER2-low status in advanced breast cancer patients treated with CDK4/6 inhibitors: is it predictive of outcome?**
Marcin Kubeczko, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland
- 12:00 - 12:00 **232P - Assessment of treatment outcomes with Everolimus and Exemestane after CDK 4/6 inhibitors in hormone receptor positive metastatic breast cancer patients in Clatterbridge Cancer Centre, Liverpool.**
Smriti Gaur, The Clatterbridge Cancer Centre - Liverpool, Liverpool, United Kingdom
- 12:00 - 12:00 **233P - Real world first line (1L) treatment selection for Australian patients (pts) with hormone receptor positive advanced breast cancer (HR+ ABC)**
Vanessa Wong, WEHI, Ballarat Health Services - Grampians Health, Western Health, Parkville, Australia
- 12:00 - 12:00 **234P - A retrospective analysis to assess the impact of interaction between CDK4/6 inhibitors and proton pump inhibitors on clinical outcomes in metastatic breast cancer patients.**
Maitreyee Rai, Allegheny Health Network Cancer Institute, Pittsburgh, United States of America
- 12:00 - 12:00 **235P - Advancing Treatment Choices: CDK4/6 Inhibitor Switching in HR+/HER2-Metastatic Breast Cancer**
Paola Zagami, European Institute of Oncology IRCCS, Milan, Italy
- 12:00 - 12:00 **236P - Survival outcomes of patients (pts) with metastatic lobular breast cancer (mLBC) receiving cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): a retrospective analysis**
Grazia Castellano, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy
- 12:00 - 12:00 **237P - Overall survival (OS) estimation using target trial emulation of major randomized controlled trials (RCTs) with the ESME metastatic breast cancer (MBC) real-world data (RWD)**
Alison Antoine, Center Leon Berard, LYON, France
- 12:00 - 12:00 **238P - Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovativeness, trials, endpoints, and price**
Julia Caroline Michaeli, Breast Center and CCC Munich, BZKF, University Hospital Munich, LMU Munich, Munich, Germany
- 12:00 - 12:00 **239P - Genomic landscape of metastatic ER+/HER2- breast cancer (BC) with loss of estrogen (ER) and/or progesterone (PR) receptor**



Ilenia Migliaccio, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy

- 12:00 - 12:00 **240P - Age at diagnosis and survival in metastatic breast cancer (MBC)**
Kristen Brantley, Dana-Farber Cancer Institute, Boston, United States of America
- 12:00 - 12:00 **241P - Real-World Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer- Multi-Institutional Retrospective Cohort Study in Japan-**
Reiko Mitsueda, Sagara Hospital, Kagoshima, Japan
- 12:00 - 12:00 **242P - An artificial intelligence (AI)-based model to predict conversion from HER2-0 primary breast cancer (BC) to HER2-low phenotype at relapse**
Federica Miglietta, University of Padova, Padova, Italy
- 12:00 - 12:00 **243P - Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An All-Ireland Patient-led Survey (CTRIAL-IE 23-05)**
Catherine Weadick, Cork University Hospital, Cork, Ireland
- 12:00 - 12:00 **244P - Identifying Metastatic Breast Cancer in Northern Ireland using Machine Learning Algorithms and Cancer Registry data - development and validation.**
Damien Bennett, Queen's University Belfast, Belfast, United Kingdom
- 12:00 - 12:00 **245P - Antitumor-Protumor Ratio as an Important Prognostic Biomarker in Metastatic Triple-Negative Breast Cancer: A Multicenter Cohort Study**
Jeffry Tenggara, MRCCC - Mochtar Riady Comprehensive Cancer Center - Siloam Hospitals Semanggi, South Jakarta, Indonesia
- 12:00 - 12:00 **246P - Clinical Utility of Molecular Tumor Board in Metastatic Breast Cancer**
Antonio Marra, IEO - Istituto Europeo di Oncologia IRCCS, Milan, Italy
- 12:00 - 12:00 **247P - Financial and time burden associated with living with a metastatic breast cancer (MBC) diagnosis in Ireland - An all-Ireland patient-led survey (CTRIAL-IE 23-05).**
Rachel Keogh, Galway University Hospital, Dublin, Ireland
- 12:00 - 12:00 **248P - Uncovering insensitive platitudes: A survey of people with metastatic breast cancer (MBC)**
Joanne Taylor, ABC Diagnosis - After Breast Cancer, Manchester, United Kingdom
- 12:00 - 12:00 **249P - Efficacy and tolerability of Low Dose Metronomic Chemotherapy using Capecitabine and Cyclophosphamide in Metastatic Breast Cancer.**
Karolina Larsson, The Institute of Clinical Sciences, University of Gothenburg, Göteborg, Sweden
- 12:00 - 12:00 **250P - Evolution of characteristics, real-world (rw) treatment (tx) landscape, and survival outcomes in patients (pts) with previously untreated metastatic triple-**



negative breast cancer (mTNBC) in the United States

Kevin Punie, GZA Hospitals Sint-Augustinus, Wilrijk, Belgium

- 12:00 - 12:00 **251P - Genomic alterations of breast cancer patients with leptomeningeal disease: a retrospective analysis**
Louis Larrouquere, Centre Léon Bérard, Lyon, France
- 12:00 - 12:00 **252P - Impact of informative censoring on the interpretation of progression-free survival (PFS) estimates in phase 3 randomized trials (RCT) in metastatic breast cancer (MBC).**
Yael Berner Wygoda, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, Canada
- 12:00 - 12:00 **253P - Patient-Centric Approach: Examining Quality-of-Life Incorporation in 5-Year Phase III Metastatic Breast Cancer Trials**
Shreyas Kalantri, University of Louisville, Louisville, United States of America
- 12:00 - 12:00 **254P - Development of Machine Learning models for the prediction of early progression (EP) to first line (1L) cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) therapy in oestrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC).**
Sergio Pannunzio, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- 12:00 - 12:00 **255P - A study to compare the response of conventional chemotherapy plus metformin versus conventional chemotherapy in non-diabetic metastatic breast cancer.**
Aqsa Rauf, King Edward Medical University, Lahore, Pakistan
- 12:00 - 12:00 **256P - Clinical Significance of Grade in Triple Negative Breast Cancer**
Haniya Farooq, University College Dublin, Dublin, Ireland
- 12:00 - 12:00 **257P - A low FT3/FT4 ratio as a negative prognostic factor in patients with metastatic breast cancer**
Roberta Scafetta, Policlinico Universitario Campus Bio-Medico, Roma, Italy
- 12:00 - 12:00 **258P - Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France**
Mario Campone, ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, France
- 12:00 - 12:00 **259P - Analysis of Survival Outcomes in Breast Cancer Patients with Brain Metastases: A Comprehensive Study Utilizing the National Cancer Database**
Vivek Podder, Miami Cancer Institute - Baptist Health South Florida, Miami, United States of America

12:00 - 12:00



260P - LUZERN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer

Salvador Blanch, Hospital Quirón Valencia, Valencia, Spain

12:00 - 12:00 **261TiP - TROPION-Breast05: Phase (Ph) 3 study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)**

Peter Schmid, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

12:00 - 12:00 **262TiP - PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan**

Manfred Welslau, Klinikum Aschaffenburg, Aschaffenburg, Germany

12:00 - 12:00 **263TiP - IMPLementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs (IMPORTANT trial) - a pragmatic randomized-controlled trial**

Antonis Valachis, Örebro University Hospital, Örebro, Sweden

12:00 - 12:00 **264TiP - TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer**

Melinda Telli, Stanford University School of Medicine, Stanford, United States of America

12:00 - 12:00 **265TiP - SOLTI-2201 ACROSS-TROP2 trial - A phase II study to identify predictive biomarkers of Sacituzumab Govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer**

Eva Ciruelos, Hospital Universitario 12 de Octubre / SOLTI Cancer Research Group, Madrid, Spain

12:00 - 12:00 **272P - Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT Study**

Noelle Vrancken Peeters, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

12:00 - 12:00 **273P - Experiences and preferences about information on treatment (tx)-related side effects (SE) among patients (pts) with early breast cancer (EBC)**

Antonio Di Meglio, Gustave Roussy, Villejuif, France

12:00 - 12:00 **274P - Efficacy of surgical gloves (SG) as compression therapy versus frozen gloves (FG) to prevent paclitaxel-induced peripheral neuropathy (PN): the trial ELEGANT**

Aurélia Joureau-Chabert, Centre Léon Bérard, Lyon, France



- 12:00 - 12:00 **275P - Clinical and socioeconomic risk factors of prolonged opioid use after breast cancer: A Danish population-based study**
Kirsten Woolpert, Aarhus University and Aarhus University Hospital, Aarhus N, Denmark
- 12:00 - 12:00 **276P - Pitfalls and consequences of insufficient data recording of patient reported outcomes (PROs) in metastatic breast cancer trials**
Can Ünal, IQWiG - Institute for Quality and Efficiency in Health Care, Köln, Germany
- 12:00 - 12:00 **277P - Descriptive analysis of hepatic safety for patients (pts) with HR+/HER2- breast cancer (BC) treated with ribociclib (RIB) + endocrine therapy (ET)**
Nadia Harbeck, Ludwig Maximilian University Hospital of Munich, Munich, Germany
- 12:00 - 12:00 **278P - Exploring Quality of Life in Women with Early Breast Cancer: A Multi-Center Cross-Sectional Study**
Ana Dugonjic Okrosa, University of Zagreb - Faculty of Pharmacy and Biochemistry, ZAGREB, Croatia
- 12:00 - 12:00 **279P - Incidence, risk factors and management of medication-related osteonecrosis of the jaw in breast cancer patients treated with Zoledronic Acid or Denosumab over a 5-year period in a UK tertiary institution**
Oyeyemi Akala, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
- 12:00 - 12:00 **280P - Outcomes of Women With Early-Stage Triple Negative Breast Cancer (TNBC) in Connection With Age and Other Socio-demographic Factors: A Population Based Cohort Study**
Shahid Ahmed, Saskatoon Cancer Centre University of Saskatchewan, Saskatoon, Canada
- 12:00 - 12:00 **281P - Psychological distress in parents with cancer and its association with parenting concerns, self-efficacy and emotion regulation - A cross sectional questionnaire study**
Maria Romare Strandh, Uppsala University, Uppsala, Sweden
- 12:00 - 12:00 **282P - Metabolic Syndrome and Survival in Breast Cancer Survivors: A Systematic Review and Meta-Analysis**
Helene Borup, Aarhus University and Aarhus University Hospital, Aarhus, Denmark
- 12:00 - 12:00 **283P - Navigating Sexuality and Hormone Therapy in Early Luminal Breast Cancer**
Tiago Pina Cabral, Centro Hospitalar de Lisboa Ocidental E.P.E. (CHLO)-Hospital São Francisco Xavier (HSFX), Lisbon, Portugal
- 12:00 - 12:00 **284P - Risk Assessment for Systemic Recurrence in HER2-Low Breast Cancer: Evaluating Hormone Receptors and Immunohistochemical Profiles**
Victor Baylon-Valdez, Centro Estatal de Cancerológica de Chihuahua, Chihuahua, Mexico
- 12:00 - 12:00 **285P - Survivorship care plans and recurrence detection in breast cancer patients**



Lorenzo Belluzzi, Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, Italy

- 12:00 - 12:00 **286P - Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: results from the PRO4All project**
Anna Amela Valsecchi, University of Turin, A.O.U. Città della Salute e della Scienza di Torino, Ospedale Molinette, Turin, Italy
- 12:00 - 12:00 **287P - Clinico-pathological features and survival outcome of Inflammatory breast cancer: An Indian Scenario**
Ajay Gogia, Institute Rotary Cancer Hospital, New Delhi, India
- 12:00 - 12:00 **289P - Evaluation of breast skin/nipple-areolar complex sensation and quality of life after nipple-sparing mastectomy followed by reconstruction**
Beatriz Polita, Riga Stradins University, Riga, Latvia
- 12:00 - 12:00 **290P - Adverse events (AEs) and impact on quality of life (QoL) of antibody-drug conjugates (ADC) in the treatment of metastatic breast cancer (mBC): a systematic review and meta-analysis of randomized controlled trials (RCTs)**
Marta Perachino, IRCCS Ospedale Policlinico San Martino and Università degli Studi di Genova Department of Internal Medicine and Medical Sciences (DiMI), Genova, Italy
- 12:00 - 12:00 **291P - Perceptions of Antibody Drug Conjugate (ADC)-induced Nausea and Vomiting: Results of a Survey of Healthcare Providers at ESMO**
Giampaolo Bianchini, IRCCS Ospedale San Raffaele, Milan, Italy
- 12:00 - 12:00 **292P - Association between Adverse Childhood Events and Baseline Cognitive Functioning in Patients with Localized Breast Cancer.**
Ayelet Shai, Rambam Health Care Campus, Haifa, Israel
- 12:00 - 12:00 **293P - Evaluating Chemotherapy Side Effects in Moroccan Breast Cancer Patients and Introducing an AI Mobile Health App for Remote Support: A Comprehensive Approach**
Farah Choulli, Cadi Ayyad university, Faculty of Medicine and Pharmacy, Marrakech, Morocco, Marrakech, Morocco
- 12:00 - 12:00 **294P - Breast cancer patient driven research agenda developed for and by breast cancer patients**
Marjolein Scholten, BVN - Borstkankervereniging Nederland, Utrecht, Netherlands
- 12:00 - 12:00 **295P - Climate Change Impact and Sustainability: A survey of Breast International Group (BIG) Members**
Seamus O'Reilly, RCSI House, Dublin, Ireland
- 12:00 - 12:00 **296P - Management of the sexual dysfunction in breast cancer survivor women on adjuvant therapy**



Sophio Khundadze, TSMU - Tbilisi State Medical University, Tbilisi, Georgia

12:00 - 12:00 **297P - Modified Delphi Consensus on Interventions for Radiation Dermatitis in Breast Cancer: A Canadian Expert Perspective**

Tarek Hijal, McGill University Health Centre - Cedars Cancer Center, Montreal, Canada

12:45 - 13:45 **Type: Industry Satellite Symposium** **Hamburg Hall**
Title: MSD - Addressing treatment questions in early breast cancer: A case-based approach
Chair(s): Rebecca Dent, Singapore

12:45 - 12:50 **Welcome: Introduction and objectives**

Rebecca Dent, NCCS - National Cancer Centre Singapore, Singapore, Singapore

12:50 - 13:05 **Case 1: How to manage adjuvant treatment in TNBC**

Rebecca Dent, NCCS - National Cancer Centre Singapore, Singapore, Singapore

13:05 - 13:20 **Case 2: Treatment considerations for early-stage ER-low patients**

Mattea Reinisch, Kliniken Essen Mitte, Essen, Germany

13:20 - 13:35 **Case 3: When to test for gBRCAm**

Peter A. Fasching, University Hospital Erlangen, Erlangen, Germany

13:35 - 13:45 **Q&A / discussion**

Rebecca Dent, NCCS - National Cancer Centre Singapore, Singapore, Singapore



- 12:45 - 13:45** **Type: Industry Satellite Symposium** **Munich Hall**
Title: PeerView Oncology - supported by Lilly - Safeguarding patients with HR+, HER2-, high-risk early breast cancer: A practical roadmap for CDK4/6 inhibition in the adjuvant setting
Chair(s): Stephen Johnston, United Kingdom
- 12:45 - 12:50 **Welcome, introduction, and goal setting**
Stephen Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, United Kingdom
- 12:50 - 13:05 **Conducting risk assessment in HR+, HER2- EBC to identify patients at high risk of recurrence**
Joyce O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, United States of America
- 13:05 - 13:20 **Integrating latest evidence and guideline recommendations to support multifactorial clinical decisions about use of adjuvant CDK4/6 inhibition in high-risk, HR+, HER2- EBC**
Stephen Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, United Kingdom
- 13:20 - 13:35 **Mitigating adverse events, improving adherence/persistence, and maximizing treatment benefits from CDK4/6 inhibitors in high-risk, HR+, HER2- EBC**
Patrick Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
- 13:35 - 13:45 **Q&A, synthesis, and conclusions**



12:45 - 13:45 **Type: Industry Satellite Symposium** **Frankfurt Hall**
Title: Novartis - Breaking new ground with CDK4/6 inhibitors: Case-based discussions on treatment decisions in HR+/HER2- breast cancer
Chair(s): Wolfgang Janni, Germany

12:45 - 12:50 **Welcome and introduction**
Wolfgang Janni, Ulm Medical University, Ulm, Germany

12:50 - 12:55 **Unmet need in HR+/HER2- early breast cancer**
Wolfgang Janni, Ulm Medical University, Ulm, Germany

12:55 - 13:15 **Exploring CDK4/6 inhibitor clinical data in HR+/HER2- early breast cancer**
Carlos Barrios, Latin American Cooperative Oncology Group, Porto Alegre, Brazil

13:15 - 13:20 **Reviewing the treatment landscape for HR+/HER2- advanced breast cancer**
Wolfgang Janni, Ulm Medical University, Ulm, Germany

13:20 - 13:40 **Analysing first-line CDK4/6 inhibitor clinical data in HR+/HER2- advanced breast cancer**
Stephanie Graff, Warren Alpert Medical School of Brown University, Providence, United States of America

13:40 - 13:45 **Key takeaways and live Q&A**
Wolfgang Janni, Ulm Medical University, Ulm, Germany

13:15 - 14:00 **Type: Young Oncologists session** **Discussion hub (exhibition area)**
Title: Meet your mentor: Managing burnout and work-life balance
Chair(s): Rodrigo Sanchez Bayona, Spain; Pablo Mando, Argentina

13:15 - 13:15 **Mentor**
Rupert Bartsch, Medizinische Universitaet Wien, Vienna, Austria

13:15 - 13:15 **Mentor**
Christine Desmedt, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium

13:15 - 13:15 **Mentor**
Cristina Saura Manich, Vall d'Hebron University Hospital, Barcelona, Spain



14:10 - 14:40 **Type: Keynote lecture** **Berlin Hall**
Title: ESMO Breast Cancer 2024 award lecture

14:10 - 14:15 **Introduction and awarding**

14:15 - 14:40 **Award lecture to be announced**

14:50 - 16:20 **Type: Special Symposium** **Berlin Hall**
Title: Lessons from recent translational approaches
Chair(s): Marleen Kok, Netherlands; Giampaolo Bianchini, Italy

14:50 - 15:10 **A living biobank to study breast cancer progression**
Colinda Scheele, KU Leuven - VIB Campus Gasthuisberg, Leuven, Belgium

15:10 - 15:30 **Mechanisms for resistance to ADCs**
Patricia Lorusso, Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, United States of America

15:30 - 15:50 **Profiling of TME to unravel unresponsiveness to IO**
Giampaolo Bianchini, IRCCS Ospedale San Raffaele, Milan, Italy

15:50 - 16:10 **Spatial transcriptomics to better understand breast cancer**
Joakim Lundeberg, Science for Life Laboratory (SciLifeLab), Solna, Sweden

16:10 - 16:20 **Conclusions and clinical perspectives**



14:50 - 16:20	Type: Educational session Title: New adjuvant strategies for luminal cancers Chair(s): Yoon-Sim Yap, Singapore; Masakazu Toi, Japan	Hamburg Hall
14:50 - 15:10	Adjuvant CDK inhibitors: The new treatment paradigm for high risk HR+HER2-breast cancer <u>Joseph Gligorov</u> , Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, France	
15:10 - 15:30	Can novel endocrine agents optimise adjuvant therapy further? <u>Patrick Neven</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium	
15:30 - 15:50	Extended adjuvant chemotherapy for luminal cancers <u>Masakazu Toi</u> , Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan	
15:50 - 16:10	Other potential adjuvant strategies for high-risk HR+HER2- breast cancer <u>Yoon-Sim Yap</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
16:10 - 16:20	Q&A and discussion	



14:50 - 16:20	Type: Multidisciplinary Tumour Board Title: Axillary management in the post-neoadjuvant setting: Local therapy, prognostic information and quality of life (QoL) Chair(s): Erika Hamilton, United States of America; Peter Dubsy, Switzerland	Munich Hall
14:50 - 15:00	Case presentation <u>Peter Dubsy</u> , Hirslanden Klinik St. Anna, Lucerne, Switzerland	
15:00 - 15:15	The surgeon: When and how can surgeons optimize lymph node resection <u>Andre Pfob</u> , University Hospital Heidelberg, Heidelberg, Germany	
15:15 - 15:30	The radiation oncologist: Cleaning up - Defining radiation volumes <u>Orit Kaidar-Person</u> , Chaim Sheba Medical Center, Ramat Gan, Israel	
15:30 - 15:45	The medical oncologist: Systemic treatment after targeted approaches to the axilla <u>Elisabetta Munzone</u> , IEO - Istituto Europeo di Oncologia, Milan, Italy	
15:45 - 16:00	Quality of life after axillary surgery: Lymphedema and beyond <u>Fiorita Poulakaki</u> , Eurokliniki Athinon, Athens, Greece	
16:00 - 16:20	Q&A and discussion	
16:30 - 16:55	Type: Coffee break Title: Coffee Break	Exhibition area



16:45 - 18:15	Type: Proffered Paper session Title: Proffered Paper session 2 Chair(s): Suzette Delaloge, France	Berlin Hall
16:45 - 16:57	One LBA TBC	
16:57 - 17:09	One LBA TBC	
17:09 - 17:19	Invited Discussant two LBAs TBC	
17:19 - 17:29	Q&A and discussion	
17:29 - 17:41	2660 - Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: results from an international cohort study <u>Matteo Lambertini</u> , University of Genova - IRCCS San Martino, Genova, Italy	
17:41 - 17:53	1090 - Adjuvant Endocrine Therapy for Premenopausal Invasive Lobular Carcinoma (ILC): Results from SOFT and TEXT phase III studies <u>Otto Metzger</u> , Dana Farber Cancer Institute - Longwood Center, Boston, United States of America	
17:53 - 18:03	Invited Discussant 2660 and 1090 <u>Janice Wing-Hang Tsang</u> , HKBOG - Hong Kong Breast Oncology Group, Hong Kong, Hong Kong PRC	
18:03 - 18:13	Q&A and discussion	



16:45 - 18:15 **Type: Special Symposium** **Frankfurt Hall**
Title: Actionable targets to improve survival experience
Chair(s): Kelly Shanahan, United States of America; Ines Vaz Luis, France

16:45 - 17:05 **Supportive care for treatment toxicity**
Andrew Neil Tippings Davies, Trinity College Dublin, Dublin, Ireland

17:05 - 17:25 **Preventing and treating cognitive dysfunction**
Marianna Masiero, University of Milan, Milan, Italy

17:25 - 17:45 **Survivorship care plans after completing treatments for early breast cancer (incl. digital aspects)**
Ines Vaz Luis, Institut Gustave Roussy, Villejuif, Cedex, France

17:45 - 18:05 **Treating the whole person: People with metastatic breast cancer are more than cancer**
Kelly Shanahan, METAvivor, Annapolis, United States of America

18:05 - 18:15 **Q&A and discussion**

17:00 - 18:00 **Type: Controversy session** **Hamburg Hall**
Title: Radiation in the setting of pCR has to be based on pre-treatment (vs post treatment) assessment
Chair(s): Icro Meattini, Italy

17:00 - 17:10 **Introduction and first vote**
Icro Meattini, AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

17:10 - 17:30 **Pro**
Elzbieta Senkus-Konefka, Medical University of Gdansk, Gdansk, Poland

17:30 - 17:50 **Contra**
Philip Poortmans, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, Belgium

17:50 - 18:00 **Second vote and conclusions/discussion**
Icro Meattini, AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy



18:15 - 19:00	Type: Young Oncologists session Title: Vesalius talk: Finding your niche in breast cancer oncology - International collaborative groups and opportunities for YOs Chair(s): Rodrigo Sanchez Bayona, Spain; Pablo Mando, Argentina	Discussion hub (exhibition area)
18:15 - 18:15	Panellist <u>Mafalda Oliveira</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
18:15 - 18:15	Panellist <u>Kevin Punie</u> , ZAS - Ziekenhuis aan de Stroom, Antwerpen, Belgium	
18:15 - 18:15	Panellist <u>Peter Dubsy</u> , Hirslanden Klinik St. Anna, Lucerne, Switzerland	
18:30 - 19:30	Type: Industry Satellite Symposium Title: Gilead - Experts debate: Navigating the complexities of metastatic breast cancer treatment Chair(s): Peter Schmid, United Kingdom	Frankfurt Hall
18:30 - 18:40	Welcome and introduction <u>Peter Schmid</u> , Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, United Kingdom	
18:40 - 19:00	Debate topic: How would you sequence ADCs for patients with pretreated HR+/HER2- metastatic breast cancer? <u>Diana Lüftner</u> ¹ , <u>Sara Tolaney</u> ² , ¹ MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, Germany, ² Dana Farber Cancer Institute, Boston, United States of America	
19:00 - 19:20	Debate topic: What should be the standard of care treatment for patients with 2L mTNBC? <u>Diana Lüftner</u> ¹ , <u>Sara Tolaney</u> ² , ¹ MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, Germany, ² Dana Farber Cancer Institute, Boston, United States of America	
19:20 - 19:30	Q&A / discussion	



17.05.2024

08:30 - 10:00 **Type: Educational session** **Berlin Hall**
Title: Current and future standards for immunotherapies for breast cancer
Chair(s): Sibylle Loibl, Germany; Giuseppe Curigliano, Italy

08:30 - 08:50 **Beyond PDL-1: Markers for response**
Roberto Salgado, GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, Belgium

08:50 - 09:10 **Current status of immunotherapy in triple negative breast cancer (TNBC)**
Giuseppe Curigliano, IEO - Istituto Europeo di Oncologia, Milan, Italy

09:10 - 09:30 **What room for immunotherapy for non-triple negative breast cancer?**
Sung-Bae Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

09:30 - 09:50 **Where to go from here: Combinations and beyond**
Sibylle Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, Germany

09:50 - 10:00 **Q&A and discussion**

08:30 - 10:05 **Type: Mini Oral session** **Hamburg Hall**
Title: Mini Oral session 2
Chair(s): Elzbieta Senkus-Konefka, Poland; Matteo Lambertini, Italy; Yoon-Sim Yap, Singapore

08:30 - 08:35 **One LBA TBC**

08:35 - 08:40 **110MO - Statin use and early breast cancer survival: A Danish population-based cohort study using an emulated target trial approach**
Karl Harborg, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

08:40 - 08:45 **111MO - Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase 3 PANTHER trial**
Theodoros Foukakis, Karolinska Institute, Stockholm, Sweden

08:45 - 09:00 **Invited Discussant one LBA TBC, 110MO and 111MO**
Elzbieta Senkus-Konefka, Medical University of Gdansk, Gdansk, Poland

09:00 - 09:05 **268MO - Safety of vaginal estrogen therapy after early-stage breast cancer: a nationwide population-based target trial emulation.**
Elise Dumas, EPFL - Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland



- 09:05 - 09:10 **269MO - The effects of exercise on sexual health and breast cancer-specific symptom burden in women with metastatic breast cancer: Results of the multinational randomized PREFERABLE-EFFECT trial**
Martina Schmidt, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and University Medical Center Heidelberg, Heidelberg, Germany
- 09:10 - 09:15 **270MO - An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients - Results of the validation study Phase IV EORTC QLQ-BR42**
Vesna Bjelic-Radasic, Helios University Hospital Wuppertal University Witten /Herdecke, Wuppertal, Germany
- 09:15 - 09:30 **Invited Discussant 268MO, 269MO and 270MO**
Matteo Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
- 09:30 - 09:35 **112MO - Neoadjuvant study of 12 months of Abemaciclib plus Letrozole vs. Chemotherapy in HR+/HER2- highly proliferative (Ki67 \geq 20%) breast cancer: CARABELA (GEICAM/2019-01) Trial**
Miguel Martin Jimenez, Instituto de Investigación Sanitaria Gregorio Marañón. CIBERONC-ISCI. GEICAM Spanish Breast Cancer Group, Madrid, Spain
- 09:35 - 09:40 **184MO - First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): safety and efficacy update**
Timothy Anthony Yap, The University of Texas MD Anderson Cancer Center - Main Building, Houston, United States of America
- 09:40 - 09:45 **113MO - NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)**
Carlos Barrios, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil
- 09:45 - 10:00 **Invited Discussant 112MO, 184MO and 113MO**
Yoon-Sim Yap, NCCS - National Cancer Centre Singapore, Singapore, Singapore



08:30 - 10:00	Type: Special Symposium Title: The growing role of artificial intelligence (AI) in breast cancer care Chair(s): Suzette Delaloge, France; Arsela Prelaj, Italy	Munich Hall
08:30 - 08:50	Predicting breast cancer risk by image analysis <u>Mikael Eriksson</u> , Karolinska Institutet, Stockholm, Sweden	
08:50 - 09:10	Artificial intelligence analysis of pathology slides for prognostic or predictive purposes: What can it tell us and how precisely? <u>Anne Vincent-Salomon</u> , Institut Curie, Paris, France	
09:10 - 09:30	AI in breast cancer screening and diagnosis <u>Fiona Gilbert</u> , University of Cambridge, Cambridge, United Kingdom	
09:30 - 09:50	Can AI allow us to better analyse large scale clinical data? <u>Arsela Prelaj</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy	
09:50 - 10:00	Conclusions and clinical perspectives	
10:00 - 10:30	Type: Coffee break Title: Coffee Break	Exhibition area
10:30 - 12:00	Type: Educational session Title: Current roles of novel endocrine therapies in the early and late settings Chair(s): Cristina Saura Manich, Spain; Philippe Aftimos, Belgium	Berlin Hall
10:30 - 10:50	Emergent mechanisms of resistance to endocrine therapies <u>Hiroji Iwata</u> , Aichi Cancer Center Hospital, Nagoya, Japan	
10:50 - 11:10	How to monitor and detect endocrine resistance <u>François Clément Bidard</u> , Institut Curie, Paris, France	
11:10 - 11:30	Arrival of new endocrine therapies to the adjuvant setting <u>Cristina Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
11:30 - 11:50	Implementation of novel endocrine therapies and combinations in the metastatic setting <u>Philippe Aftimos</u> , Institute Jules Bordet, Anderlecht, Belgium	
11:50 - 12:00	Q&A and discussion	



10:30 - 12:00	Type: Educational session Title: Management of brain metastases from early detection to local and systemic treatments Chair(s): Emilie Le Rhun, Switzerland; Thomas Bachelot, France	Hamburg Hall
10:30 - 10:50	Is there a role for screening of brain metastases? <u>Emilie Le Rhun</u> , University Hospital Zürich, Zurich, Switzerland	
10:50 - 11:10	Evolving role of neurosurgery in brain metastases <u>Jens Gempt</u> , University Medical Center Hamburg-Eppendorf, Hamburg, Germany	
11:10 - 11:30	Radiation therapy: Present and future <u>Giuseppe Minniti</u> , Sapienza Università di Roma, Rome, Italy	
11:30 - 11:50	Advance in medical treatment <u>Nancy Lin</u> , Dana Farber Cancer Institute, Boston, United States of America	
11:50 - 12:00	Q&A and discussion	
12:00 - 12:30	Type: Lunch break Title: Lunch	Exhibition area
12:15 - 13:00	Type: Young Oncologists session Title: Meet your mentor: Academic research and use of real-world data Chair(s): Rodrigo Sanchez Bayona, Spain; Pablo Mando, Argentina	Discussion hub (exhibition area)
12:15 - 12:15	Mentor <u>Suzette Delalogue</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
12:15 - 12:15	Mentor <u>Giuseppe Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, Italy	
12:15 - 12:15	Mentor <u>Nadia Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, Germany	



12:30 - 13:30	Type: Industry Satellite Symposium Title: Daiichi Sankyo - Advance, Deliver, Challenge: ADCs and the future of HR-positive BC Chair(s): Hope Rugo, United States of America	Hamburg Hall
12:30 - 12:35	Welcome and introduction <u>Hope Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America	
12:35 - 12:50	Deliver: Established ADCs for treatment of HR-positive mBC <u>Rebecca Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, Singapore	
12:50 - 13:05	Advance: Emerging data for novel ADCs in HR-positive mBC <u>Komal Jhaveri</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, United States of America	
13:05 - 13:15	Challenge: Tailoring treatment for patients with HR-positive mBC <u>Hope Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America	
13:15 - 13:25	Q&A	
13:25 - 13:30	Meeting close <u>Hope Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, United States of America	



13:45 - 15:15	Type: Meeting highlights Title: ESMO Breast 2024 key takeaways Chair(s): Erika Hamilton, United States of America; Masakazu Toi, Japan	Berlin Hall
13:45 - 13:55	Breast cancer early detection and prevention <u>Suzette Delaloge</u> , Institut Gustave Roussy, Villejuif, Cedex, France	
13:55 - 14:10	Translational research <u>Marleen Kok</u> , Netherlands Cancer Institute, Amsterdam, Netherlands	
14:10 - 14:30	Early breast cancer <u>Erika Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, United States of America	
14:30 - 14:50	Metastatic breast cancer <u>Eva Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, Spain	
14:50 - 15:05	Supportive care <u>Anne May</u> , UMC - University Medical Center Utrecht, Utrecht, Netherlands	
15:05 - 15:15	Closure of the meeting	